News & Updates

Show Multimedia Only
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC

Adjuvant pembrolizumab continues to improve DFS in clear cell RCC

28 Sep 2022 byRoshini Claire Anthony

In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.

Adjuvant pembrolizumab continues to improve DFS in clear cell RCC

28 Sep 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer

First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer

27 Sep 2022

Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.

First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer

27 Sep 2022
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer

Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer

27 Sep 2022
Mammography uptake among Malay-Muslim women low, blamed on multilevel factors

Mammography uptake among Malay-Muslim women low, blamed on multilevel factors

26 Sep 2022 byJairia Dela Cruz

Breast cancer screening behaviour among Malay-Muslim women in Singapore appears to hinge on multilevel factors that involve not only personal relationships but also their religious beliefs and screening facilities’ availability and access.

Mammography uptake among Malay-Muslim women low, blamed on multilevel factors

26 Sep 2022